The Cancer Center Protocol Review and Monitoring System oversees and ensures the scientific merit, priorities, and progress of all cancer clinical studies conducted at the University of Virginia (UVA). A Protocol Review Committee (PRC), appointed by the UVA Cancer Center Director and administratively-supported by the Office for Clinical Research, has been given the authority and charge to carry out this mandate. The PRC is chaired by James Larner, MD. Its primary goal is to ensure that investigator- and industryinitiated cancer research studies involving human subjects conducted at the UVA Cancer Center are: (1) scientifically and statistically sound;(2) appropriately designed;(3) feasible for completion;and (4) in compliance with NIH guidelines for human studies. The PRC also plays an important role in mediating competing studies by requiring an agreed upon institutional prioritization plan, and closely monitors the accrual progress of studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-23
Application #
8635299
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
23
Fiscal Year
2014
Total Cost
$50,597
Indirect Cost
$21,480
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Melssen, Marit; Slingluff Jr, Craig L (2017) Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 47:85-92
Bullock, Timothy Nj (2017) TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines. Curr Opin Immunol 47:70-77
Scalici, Jennifer M; Arapovic, Sanja; Saks, Erin J et al. (2017) Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer 123:977-984
Shukla, Girja S; Olson, Walter C; Pero, Stephanie C et al. (2017) Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. J Transl Med 15:180
Keim-Malpass, Jessica; Mitchell, Emma M; DeGuzman, Pamela B et al. (2017) Legislative activity related to the human papillomavirus (HPV) vaccine in the United States (2006-2015): a need for evidence-based policy. Risk Manag Healthc Policy 10:29-32
Mills, Anne M; Paquette, Cherie; Terzic, Tatjana et al. (2017) CK7 Immunohistochemistry as a Predictor of CIN1 Progression: A Retrospective Study of Patients From the Quadrivalent HPV Vaccine Trials. Am J Surg Pathol 41:143-152
Rohani, Ali; Moore, John H; Kashatus, Jennifer A et al. (2017) Label-Free Quantification of Intracellular Mitochondrial Dynamics Using Dielectrophoresis. Anal Chem 89:5757-5764
Wages, N A; Slingluff Jr, C L; Petroni, G R (2017) Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies. Ann Oncol 28:696-701
O'Brien, Carleigh A; Overall, Christopher; Konradt, Christoph et al. (2017) CD11c-Expressing Cells Affect Regulatory T Cell Behavior in the Meninges during Central Nervous System Infection. J Immunol 198:4054-4061
Bullock, Timothy Nj (2017) Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer. Curr Opin Immunol 45:82-88

Showing the most recent 10 out of 472 publications